Document is current
Any future updates will be listed below
-
Authors
Allen, Alina M.
Younossi, Zobair M.
Diehl, Anna Mae
Charlton, Michael R.
Lazarus, Jeffrey V. https://orcid.org/0000-0001-9618-2299
- License Information
-
More Information
Article History
Accepted: 2 May 2024
First Online: 4 June 2024
Competing interests
: A.M.A. acknowledges grant support to her institution from the National Institutes of Health (DK128127), Novo Nordisk, Pfizer and Target Pharma and advisory board participation for Boehringer Ingelheim and Novo Nordisk outside of the submitted work. Z.M.Y. acknowledges consulting fees from Abbott, AstraZeneca, BMS, Boehringer Ingelheim, Cymabay, Gilead, GSK, Intercept, Madrigal, Merck, Novo Nordisk and Siemens outside of the submitted work. A.M.D. acknowledges grant support to her institution from Boehringer Ingelheim, GSK, Hanmi, Intercept, Inventiva, Madrigal, Novo Nordisk, Tune Therapeutics, and Viking and consulting for Boehringer Ingelheim outside of the submitted work. M.R.C. acknowledges consulting for Bristol-Myers-Squibb, Celgene, Histoindex, Intercept, Madrigal, NGM, Novo Nordisk, Pfizer, Terns, and Theratechnologies and research grants from Gilead Sciences outside of the submitted work. J.V.L. acknowledges grants and speaker fees from AbbVie, Gilead Sciences, MSD, Novo Nordisk and Roche Diagnostics to his institution, grants from Boehringer Ingelheim, GSK and Madrigal to his institution, speaker fees from Echosens, Janssen, Novo Nordisk and ViiV, and consulting fees from Echosens, Gilead Sciences, GSK, Novavax and Roche Diagnostics outside of the submitted work.
